title: Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration.
authors.forename: F
authors.initials: F
authors.lastname: Pea
authors.forename: L
authors.initials: L
authors.lastname: Brollo
authors.forename: M
authors.initials: M
authors.lastname: Lugano
authors.forename: L
authors.initials: L
authors.lastname: Dal Pos
authors.forename: M
authors.initials: M
authors.lastname: Furlanut
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D015377:Cilastatin / Q000494:pharmacology; D000077728:Cilastatin, Imipenem Drug Combination; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D016903:Drug Monitoring; D006440:Hemofiltration; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D016030:Kidney Transplantation; D008297:Male; D009102:Multiple Organ Failure / Q000150:complications; D018805:Sepsis / Q000150:complications; D012709:Serum Albumin / Q000172:deficiency*; D017334:Teicoplanin / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics
chemical_list: D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D012709:Serum Albumin; D015377:Cilastatin; D017334:Teicoplanin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination